Progestogens in prostatic cancer

A series of 20 patients with a histological diagnosis of prostatic cancer were treated with high doses of MAP (6alpha-methyl-17alpha-hydroxyprogesterone acetate). No response was noted in 9 patients with prostatic cancer in relapse. Objective and/or subjective response was noted in 6 of 11 patients who were untreated at the time of diagnosis.